THE ROLE OF AZACITIDINE IN THE TREATMENT OF ELDERLY PATIENTS WITH AML - RESULTS OF A RETROSPECTIVE MULTICENTER STUDY

被引：0

作者：

Tombak, A. ^{[1
]}

Ucar, M. A. ^{[1
]}

Akdeniz, A. ^{[1
]}

Tiftik, E. N. ^{[1
]}

Sahin, D. ^{[2
]}

Akay, O. M. ^{[2
]}

Yildirim, M. ^{[3
]}

Nevruz, O. ^{[3
]}

Kis, C. ^{[4
]}

Gurkan, E. ^{[4
]}

Solmaz, S. Medeni ^{[5
]}

Ozcan, M. A. ^{[5
]}

Yildirim, R. ^{[6
]}

Berber, I. ^{[7
]}

Erkurt, M. A. ^{[7
]}

Tuglular, T. Firatli ^{[8
]}

Tarkun, P. ^{[9
]}

Yavasoglulo, I. ^{[10
]}

Dogu, M. N. ^{[11
]}

Sari, I. ^{[11
]}

Merter, M. ^{[12
]}

Ozcan, M. ^{[12
]}

Yildizhan, E. ^{[13
]}

Kaynar, L. ^{[13
]}

Mehtap, O. ^{[9
]}

Uysal, A. ^{[14
]}

Sahin, F. ^{[14
]}

Salim, O. ^{[15
]}

Sungur, M. A. ^{[16
]}

机构：

[1] Mersin Univ, Fac Med, Internal Med Hematol, Mersin, Turkey

[2] Eskisehir Osmangazi Univ, Internal Med Hematol, Eskisehir, Turkey

[3] GATA, Internal Med Hematol, Ankara, Turkey

[4] Cukurova Univ, Internal Med Hematol, Adana, Turkey

[5] Dokuz Eylul Univ, Internal Med Hematol, Izmir, Turkey

[6] Ataturk Univ, Internal Med Hematol, Erzurum, Turkey

[7] Malatya Inonu Univ, Internal Med Hematol, Malatya, Turkey

[8] Marmara Univ, Internal Med Hematol, Istanbul, Turkey

[9] Kocaeli Univ, Internal Med Hematol, Kocaeli, Turkey

[10] Adnan Menderes Univ, Internal Med Hematol, Aydin, Turkey

[11] Denizli Pamukkale Univ, Internal Med Hematol, Denizli, Turkey

[12] Ankara Univ, Internal Med Hematol, TR-06100 Ankara, Turkey

[13] Kayseri Erciyes Univ, Internal Med Hematol, Kayseri, Turkey

[14] Ege Univ, Internal Med Hematol, Izmir, Turkey

[15] Akdeniz Univ, Internal Med Hematol, TR-07058 Antalya, Turkey

[16] Duzce Univ, Internal Med Hematol, Duzce, Turkey

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E938

引用

页码：374 / 375

页数：2

共 50 条

[21] Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer
Reinhard Stauder
Sonja Burgstaller
Martin Schreder
Christoph Tinchon
Michael Pfeilstocker
Susanne Steinkirchner
Thomas Melchardt
Martina Mitrovic
Michael Girschikofsky
Alois Lang
Peter Krippl
Thamer Sliwa
Alexander Egle
Werner Linkesch
Daniela Voskova
Hubert Angermann
Richard Greil
Journal of Hematology & Oncology, 6
[22] UPDATED RESULTS FROM A PHASE 2 STUDY OF PRACINOSTAT (P) IN COMBINATION WITH AZACITIDINE (AZA) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Garcia-Manero, G.
Atallah, E.
Khaled, S.
Arellano, M.
Patnaik, M.
Esquibel, V.
Wood, K.
Medeiros, B.
HAEMATOLOGICA, 2015, 100 : 216 - 216
[23] Efficacy and tolerablity of azacitidine treatment in patients with MDS, AML and CMML
Biedma, A.
Avellaneda, C.
Berruga, J.
Tallon, D.
Ferrer, C.
Anguita, M.
LEUKEMIA RESEARCH, 2013, 37 : S97 - S97
[24] EFFICACY AND TOLERABLITY OF AZACITIDINE TREATMENT IN PATIENTS WITH MDS, AML AND CMML
Biedma, A.
Avellaneda, C.
Berruga, J.
Tallon, D.
Ferrer, C.
Anguita, M.
HAEMATOLOGICA, 2013, 98 : 589 - 589
[25] A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma
Kozyreva, Olga N.
Chi, Dorcas
Clark, Jeffrey W.
Wang, Hejing
Theall, Kathy P.
Ryan, David P.
Zhu, Andrew X.
ONCOLOGIST, 2011, 16 (03): : 310 - 318
[26] An early-phase study of azacitidine and lenalidomide for untreated elderly acute myeloid leukemia (AML) patients
Pollyea, D. A.
Kohrt, H. E.
Rajwanshi, R.
Gallegos, L.
Berube, C.
Coutre, S. E.
Gotlib, J. R.
Liedtke, M.
Mitchell, B. S.
Medeiros, B. C.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Azacitidine Use in MDS and AML Patients: Best Selection for Better Results
Michallet, Mauricette
Sobh, Mohamad
Morisset, Stephane
Champigneulle, Carine
Ranchon, Florence
Detrait, Marie Y.
Labussiere-Wallet, Helene
Ducastelle, Sophie
Nicolini, Franck E.
Chelghoum, Youcef
Thomas, Xavier
Le Jeune, Caroline
Wattel, Eric
Rioufol, Catherine
Barraco, Florenza
BLOOD, 2012, 120 (21)
[28] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U Platzbecker
M Wermke
J Radke
U Oelschlaegel
F Seltmann
A Kiani
I-M Klut
H Knoth
C Röllig
J Schetelig
B Mohr
X Graehlert
G Ehninger
M Bornhäuser
C Thiede
Leukemia, 2012, 26 : 381 - 389
[29] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Platzbecker, U.
Wermke, M.
Radke, J.
Oelschlaegel, U.
Seltmann, F.
Kiani, A.
Klut, I-M
Knoth, H.
Roellig, C.
Schetelig, J.
Mohr, B.
Graehlert, X.
Ehninger, G.
Bornhaeuser, M.
Thiede, C.
LEUKEMIA, 2012, 26 (03) : 381 - 389
[30] LONG DURATION OF RESPONSE TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES. MULTICENTER RETROSPECTIVE STUDY OF 36 PATIENTS
Finelli, C.
Clissa, C.
Voso, M. Teresa
Spiriti, M.
Breccia, M.
Gaidano, G.
Crugnola, M.
Giannini, M. Benedetta
Poloni, A.
Bosi, C.
Naso, V.
Follo, M. Y.
Mongiorgi, S.
Martinelli, G.
Cocco, L.
Cavo, M.
HAEMATOLOGICA, 2013, 98 : 308 - 309

← 1 2 3 4 5 →